Ionis Pharmaceuticals Drops Another After Phase 3 Setback
Ionis Pharmaceuticals dropped again after a Phase 3 failure in transthyretin amyloid cardiomyopathy, triggering a bro...
Review year-by-year annual performance for index funds to uncover patterns that inform proactive asset allocation.
25,727 articlesIonis Pharmaceuticals dropped again after a Phase 3 failure in transthyretin amyloid cardiomyopathy, triggering a bro...
An unusual trading day put Lucid Group in the spotlight after rumors swirled about bankruptcy or going private. Learn...
Meta Platforms Looks Abandon a $174B AI bet signals a strategic pivot. This article breaks down what it means for inv...
New GDP figures show fourth-quarter growth remained positive but cooled, challenging the notion of a looming slowdown...
As biotech investors digest Recursion's latest quarterly results, this Deep Dive breaks down what recursion (rxrx) 20...
Bank of America reinstates Ford with a Buy rating and a $17 target, while Rivian is downgraded to Underperform with a...
Target stock surged after the latest earnings release, sending investors back to the question: is this the start of a...
As velocity financial readies its quarterly release, investors seek clues about growth, profitability, and risk. This...
Versant Media Group launches a CNBC-based direct-to-consumer platform for retail investors, pairing journalism with A...
Firefly Aerospace surprised investors with a better-than-expected Q4 result, sending its stock higher before ending t...
JetBlue jumped 18% after announcing a multi-year partnership with Boston Legacy FC as the official airline, while Del...
In the (dxc) 2026 earnings call, executives outlined the road ahead for DXC Technology's growth, margins, and free ca...